

## ***Research Article***

### **High viral SARS-CoV-2 load in placenta of patients with hypertensive disorders after COVID-19**

#### **during pregnancy**

Fabre M<sup>a,b</sup>, Calvo P<sup>b,c</sup>, Ruiz-Martinez S<sup>b,c,d</sup>, Peran M<sup>a,b</sup>, Oros D<sup>b,c,d</sup>, Medel Martinez A<sup>e</sup>, Strunk M<sup>ef</sup>, Benito R<sup>g</sup>, Schoorlemmer J<sup>b,h,i</sup>, Paules C<sup>b,c,d</sup>

a Instituto de Investigación Sanitario de Aragón (IIS Aragón) Biochemistry Department, Hospital Clínico Universitario Lozano Blesa Zaragoza, Spain

b Placental pathophysiology & fetal programming research group, B46\_20R & GIIS-028 del IISA

c Instituto de Investigación Sanitario de Aragón (IIS Aragón), Obstetrics Department, Hospital Clínico Universitario Lozano Blesa Zaragoza, Spain

d Red de Salud Materno Infantil y del Desarrollo (SAMID), RETICS. Instituto de Salud Carlos III (ISCIII), Subdirección General de Evaluación y Fomento de la Investigación y Fondo Europeo de Desarrollo Regional (FEDER) Ref: RD16/0022/0013

e Laboratorio Satélite, Instituto Aragonés de Ciencias de la Salud (IACS), Centro de Investigación Biomédica de Aragón (CIBA), Zaragoza, Spain

f Sequencing and Functional Genomics, Instituto Aragonés de Ciencias de la Salud (IACS), Centro de Investigación Biomédica de Aragón (CIBA), Zaragoza, Spain

g Microbiology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. Universidad de Zaragoza. IIS Aragón

h Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain

i ARAID Foundation, Zaragoza, Spain.

Short Title: SARS-CoV-2 viral load in placenta of patients with hypertensive disorders

Corresponding Author: Schoorlemmer J

Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain

Calle de San Juan Bosco, 13, 50009 Zaragoza, Spain

Tel.: +34 976 715 412; +34 672 022 215;

[jonas@araid.es](mailto:jonas@araid.es)

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Number of Tables: 2

Number of Figures: 4

Word count: 3686

Keywords: SARS-CoV-2, placenta, hypertensive disorders of pregnancy, COVID-19, placental viral load

1

2 **Abstract**

3 **Introduction:** Studies described an increased frequency of hypertensive disorders of  
4 pregnancy after a COVID-19 episode. There is limited evidence about SARS-CoV-2 viral load in  
5 placenta. This study aimed to investigate the relationship between SARS-CoV-2 viral load in  
6 placenta and clinical development of HDP after COVID-19 throughout different periods of  
7 gestation.

8 **Methods:** This was a case-control study in women with and without gestational hypertensive  
9 disorders (HDP) after SARS-CoV-2 infection diagnosed by RT-PCR during pregnancy. Patients  
10 were matched by gestational age at the moment of COVID-19 diagnosis. We performed an  
11 analysis of SARS-CoV-2 RNA levels in placenta.

12 **Results:** A total of 28 women were enrolled. Sixteen patients were diagnosed with COVID-19  
13 during the third trimester and the remaining twelve patients in the others trimesters. Ten  
14 placentas (35.7%) were positive for SARS-CoV-2, nine of them (90%) belonged to the HDP  
15 group versus one (10%) in control group ( $p=0.009$ ). Those cases with the highest loads of viral  
16 RNA developed severe-preeclampsia.

17 **Conclusion:** The presence of SARS-CoV-2 was more frequent in placentas of patients with HDP  
18 after COVID-19. There seems to be a relationship between high viral load in the placenta and  
19 the development of hypertensive disorders. We found SARS-CoV-2 viral load in placenta after  
20 birth in mothers infected at the first half of pregnancy, but with negative nasopharyngeal RT-  
21 PCR at delivery. Our data suggest that SARS-CoV-2 infection during pregnancy could trigger  
22 gestational hypertensive disorders through placenta-related mechanisms.

23

24

## 25 INTRODUCTION

26 Several international studies have recently suggested an increase in preeclampsia and other  
27 hypertensive disorders of pregnancy (HDP) associated with SARS-CoV-2 infection during  
28 pregnancy [1,2,3,4] with classic signs and symptoms related to preeclampsia, such as  
29 hypertension, proteinuria, thrombocytopenia, elevated liver enzymes [5,6]. Preeclampsia (PE)  
30 is a pregnancy-specific multisystem disorder characterized by endothelial dysfunction that  
31 leads to the release of soluble factors into de maternal circulation responsible for the multi-  
32 organ injury [7]. These so-called preeclampsia-like syndromes are in some way clinical  
33 manifestations of maternal endothelial dysfunction.

34 The clinical manifestations of the SARS-CoV-2 infection support a key role for endothelial  
35 dysfunction in the pathobiology of this condition. SARS-CoV-2 infection induces an  
36 endotheliitis in different organs as a direct consequence of viral infection and the host  
37 inflammatory response [8,9]. Angiotensin-converting enzyme 2 (ACE2) is the major cellular-  
38 entry receptor for SARS-CoV-2 virus [10]. ACE2 is present prominently in the alveoli, but also in  
39 endothelial cells, which can be directly infected by the virus [11]. Besides, cytokine release  
40 syndrome can also drive endothelial damage independently [12]. Consequently, a distinctive  
41 feature of SARS-CoV-2 infection is vascular harm, with severe endothelial injury, widespread  
42 thrombosis and microangiopathy, in response to endothelial damage. Therefore, endothelial  
43 dysfunction seems to be the pathophysiological substrate for severe COVID-19 complications.

44 It is at present unknown how COVID-19 is associated with increased frequency of HDP (and  
45 especially PE) and whether similar mechanisms operate. COVID-19 associated PE-like disease  
46 may be an indirect result of maternal disease or more directly related to the presence of SARS-  
47 CoV-2 in the placenta. While initial studies had suggested that SARS-CoV-2 invades the  
48 placenta in some cases [13, 14, 15], posterior data suggest that is not very common [16, 17, 18,

49 19]. Consistent with a low frequency presence of SARS-CoV-2 in the placenta [22], vertical  
50 transmission is rather infrequent [21]: a systematic review reported a rate of 3.2% vertical  
51 transmission in mothers who tested positive for SARS-CoV-2 (diagnosed by RT-PCR) during the  
52 third trimester of pregnancy [22]. A recent study of placentas taken from COVID-19 positive  
53 mothers [23] describes a low-level presence of RNA in about half of placentas. No substantial  
54 histopathological, maternal, or neonatal outcome features were detected associated with this  
55 low level of viral RNA. However, a high SARS-CoV-2 RNA level was detected in only one patient,  
56 who exhibited severe placental injury in the form of extensive fibrin deposition, necrosis of the  
57 syncytiotrophoblast layer of the villi and apoptosis. This observation fits the hypothesis that  
58 only limited placental pathology is associated with COVID-19, except for cases with very high  
59 SARS CoV2 RNA levels, the latter indicative of high viral load.

60

61 Considering the increase in hypertensive disorders in COVID-19 patients, this study aimed to  
62 investigate the relationship between SARS-CoV-2 viral load in placental tissue at birth and the  
63 development of preeclampsia or gestational hypertension after COVID-19 throughout different  
64 periods of gestation. The clinical history of three cases of preeclampsia, with positive placental  
65 PCR tests for SARS-CoV-2 during each of the three semesters of pregnancy, is described in  
66 detail as an example.

67

## 68 **Materials and Methods**

69 We conducted a case-control study in women diagnosed with COVID-19 during pregnancy with  
70 and without gestational hypertensive disorders. We perform an analysis of SARS-CoV-2 RNA  
71 levels in placental tissue and SARS-CoV-2 antibodies in umbilical cord. Patients were recruited  
72 at the moment of delivery between May 2020 and February 2021 at a tertiary University

73 Center. Cases were defined as women who tested positive for SARS-CoV-2 during pregnancy  
74 and were diagnosed with gestational hypertensive disorders. Controls, defined as SARS-CoV-2  
75 positive women without HDP during pregnancy, were paired by gestational age at the moment  
76 of SARS-CoV-2 diagnosis.

77

78 SARS-CoV-2 infection was diagnosed based on positive RT-PCR test for SARS-CoV-2 from  
79 nasopharyngeal swabs. RT-PCR test kits from different companies were used: Viasure (CerTest  
80 Biotec, Zaragoza, Spain), M2000 SARS-CoV-2 Assay (Abbott RealTime SARS-CoV-2 Assay,  
81 Abbott Molecular, Abbott Park, IL, USA), TaqPath COVID-19 (Thermo Fisher Scientific, USA-  
82 FDA) and Alinity SARS-CoV-2 (Abbott Alinity, Abbott Molecular, Abbott Park, IL, USA).  
83 Information on these test kits are listed in Supplementary Table1. As suggested by the  
84 manufacturer for nasopharyngeal specimens, cycle threshold (CT) values below 37 were taken  
85 as positive. Besides, all women who were hospitalized for delivery were screened for SARS-  
86 CoV-2 infection using RT-PCR on nasopharyngeal swabs shortly before giving birth. However, in  
87 the case of pregnant women who had already overcome the infection, PCR-RT was only  
88 performed around delivery if the latest negative PCR test was more than 3 months ago. As a  
89 result, four patients (3, 4, 15 and 16) were not tested for SARS-CoV-2 infection at the time of  
90 delivery. Prophylactic treatment with low molecular weight heparin for 14 days was applied to  
91 COVID-19 women diagnosed by RT-PCR [24]. COVID-19 has been divided into three types [25]:  
92 asymptomatic infection refers no clinical symptoms or signs; mild infection refers symptoms  
93 such as fever, cough, headache, anosmia and asthenia; and severe infection refers dyspnea,  
94 hypoxemia accompanied by chest imaging compatible with pneumonia and respiratory  
95 infection.

96 Placental tissue samples were taken at the moment of delivery, taking villous tissue while  
97 carefully trying to avoid the overlying maternal tissue. Placental samples, approximately 1 cm<sup>3</sup>  
98 in size, were placed into tubes containing 1 ml of preservative solution (RNAlater Fisher  
99 Scientific) at 4°C. After 24h, excess RNAlater was removed, and the samples were stored at  
100 -80°C. Tissue was homogenized, RNA was extracted, treated with DNase I, repurified and  
101 resuspended as previously described [26]. Concentrations were measured using Nanodrop,  
102 100 ng of RNA was used in downstream PCR analysis. RT-PCR for SARS-CoV-2 in placenta tissue  
103 samples was performed using the TaqPath COVID-19 CE-IVD RT-PCR kit (Catalog Number  
104 A48067; Life Technologies Europe, Bleiswijk, The Netherlands) on a QuantStudio5 (Applied  
105 Biosystems; ThermoFisher Scientific) apparatus. The limit of detection of this kit is listed as 10  
106 GCEs (Genomic Copy Equivalents). As this assay targets N, ORF1ab and S genes, only samples  
107 with three positive targets were considered as SARS-CoV-2 positive. SARS-CoV-2 tissue load in  
108 placenta is referred to in the manuscript as viral load and is expressed as CT values of RT-PCR.

109 We collected umbilical cord plasma in EDTA and samples were centrifuged. Serological assays  
110 were determined on the same day by chemiluminescent microparticle immunoassays for  
111 quantitative detection of SARS-CoV-2 IgG. The SARS-CoV-2 IgG assay is designed to detect IgG  
112 antibodies to the nucleocapsid protein of SARS-CoV-2. (IgG; SARS-CoV-2 IgG Assay, Abbott  
113 Laboratories Ireland, Dublin, Ireland) and IgM+IgA antibodies (IgM+IgA; COVID-19 VIRCLIA  
114 IgM+IgA, Vircell Microbiologists, Granada, Spain).

115 Gestational hypertensive disorders were divided into four categories, defined according to the  
116 criteria proposed by American college of Obstetrics and Gynaecologists [27]: preeclampsia,  
117 chronic hypertension, chronic hypertension with superimposed preeclampsia and gestational  
118 hypertension. First trimester risk of early-onset preeclampsia was retrospectively calculated  
119 according to maternal characteristics, obstetric history, maternal blood pressure, maternal

120 serum pregnancy-associated plasma protein-A and uterine artery pulsatility index, using  
121 SsdwLab6 version 6.1 package (SBP Soft 2007 S.L.) [28].

122 Clinical characteristics, laboratory results, maternal and neonatal outcomes were collected  
123 from medical records. All patients provided written informed consent. The study was approved  
124 by the Research Ethics Committee of the Community of Aragon (C.I. PI21/155 and COL21/000)  
125 and all patients provided written informed consent.

126 Statistical analysis was performed using SPSS 22.0. Categorical variables were presented as  
127 frequencies or percentages. Continuous variables were presented using mean  $\pm$  standard  
128 deviation, median, or range. For continuous variables, Shapiro Wilk tests of normality were  
129 used to evaluate the distributions. Data were analysed using Student t test or Mann–Whitney  
130 U test. Statistical significance was considered  $p < 0.05$ .

131

## 132 **Results**

133 Fourteen women in the case group (COVID-19 positive and diagnosis of HDP) and fourteen  
134 women in the control group, matched for gestational age at the time of COVID-19 diagnosis,  
135 were included. Out of those 14 cases, 9 cases (64.3%) had preeclampsia and five cases (35.7%)  
136 had gestational hypertension. Demographic and clinical data, as well as perinatal and neonatal  
137 outcomes are shown in table 1. There were no significant differences in maternal age,  
138 maternal weight, risk of preeclampsia at 1<sup>o</sup> trimester, nulliparity rate and diabetes mellitus  
139 between the two groups. The vast majority of patients, eight pairs, represent pregnant women  
140 who were diagnosed with COVID-19 during the third trimester, whereas five pairs in the  
141 second trimester and only one pair in the first trimester. Mean gestational age at delivery was  
142 268.1 days in the case group and 278.9 days in the control group ( $p=0.005$ ). Women with HPD  
143 also exhibited lower birthweight compared with the control group (2852.5g SD 467.0 versus

144 3282.9g SD: 435.9;  $p=0.005$ ). There were no significant differences for small for gestational  
145 age, umbilical arteria  $ph<7.1$ . Induced labor and cesarean was significantly more frequent in  
146 the HDP group compared to controls ( $p= 0.003$  and  $p=0.015$ , respectively).

147 The chronology of diagnosis of HDP and SARS-CoV-2 infection of each patient is summarized in  
148 table 2. There was no significant difference in the severity of SARS-CoV-2 symptoms initial  
149 between the groups ( $p= 0.341$ ). Thirteen had no symptoms, thirteen patients had mild and  
150 only two patients had severe SARS-CoV-2 infection (Table 2). No patient required admission to  
151 the intensive care unit.

152 Using a sensitive RT-PCR assay, ten placentas (35.7%) from SARS-CoV-2 positive women during  
153 pregnancy, tested positive for SARS-CoV-2 RNA at birth. In the case group, we found nine  
154 positive placentas (9/10, 90%) while in control group only one placenta (1/10, 10%) were  
155 positive ( $p=0.009$ ) (shown in Fig.1). Moreover, 7 of nine 9 placentas (77.8%) belong to women  
156 diagnosed with preeclampsia. Focusing on positive placentas, we have three cases with high  
157 loads of viral RNA (CTs  $\leq 28$ ) (see below), and the remaining seven cases with low loads of viral  
158 RNA (median CT of 30.6; Interquartile range 28.7-33.9) (Table 2).

159 While only six pairs of pregnancies with positive SARS-CoV-2 tests during the first or second  
160 trimester ( $GA \leq 27$  weeks) were analyzed (Table 2), several remarkable results deserve  
161 mentioning. First, out of the six cases with HDP, six out of six had positive placental SARS-CoV-  
162 2 test at birth. In contrast, among the corresponding six control cases without HDP, only one  
163 tested positive for placental SARS-CoV-2 (Table 2).It is possible therefore, that the continued  
164 presence of SARS-CoV-2 in the placenta promotes HDP or vice versa. Moreover, out of ten  
165 pregnancies for which data are available with these early SARS-CoV-2 infections, only one  
166 mother remained positive at delivery ( $N^{\circ} 6$ ), while seven placentas tested positive. This latter

167 data suggests that infection with SARS-CoV-2 during early pregnancy may commonly result in  
168 persisting placental presence of SARS-CoV-2.

169 Finally, antibody quantification was performed for 87.5% neonates with umbilical cord blood  
170 samples. Thirteen infants tested positive for IgG on the first 10 days of life, and none tested  
171 positive for IgM+IgA. There was no significant difference between the groups in the number of  
172 neonates that tested positive for SARS-CoV-2 IgG ( $p= 0.688$ ).

173 Among the placentas that tested positive, three cases with high loads of viral RNA (Cts = 15;  
174 23; 28, respectively) represented cases of severe preeclampsia (Table 2). Case number 1  
175 (shown in Fig.2) was a woman with no medical history of interest. The estimated risk of early-  
176 onset preeclampsia in the first trimester was 1/122. She presented positive SARS-CoV-2 RT-  
177 PCR (CT: 18.7) at week 8 of gestation and infection courses asymptomatic. Two weeks later,  
178 she tested negative for SARS-CoV-2 by RT-PCR. At 35 week of gestation, she debuted with  
179 severe preeclampsia, which required admission to the hospital and treatment with intravenous  
180 labetalol and magnesium sulfate. RT-PCR for SARS-CoV-2 infection was performed at the time  
181 of admission, with a negative result. Termination of pregnancy was in week 35 + 2 for this  
182 reason. A female of 1875 grams, APGAR test was 9 and 10 at 1 and 5 minutes, respectively,  
183 and pH 7.31 without antibodies against SARS-CoV-2 was born. Placental analysis for SARS-CoV-  
184 2 was positive, with a high viral load by RT-PCR.

185 Case number 11 (shown in Fig.3) was a nulliparous woman with a spontaneous monochorionic  
186 diamniotic twin. The estimated risk of early-onset preeclampsia in the first trimester was 1/15.  
187 Pregnancy of normal course until week 26+5, when she debuted with fever, cough and  
188 myalgias. RT-PCR results for SARS-CoV-2 was positive (CT: 5.9). At 34+0 she tested negative for  
189 SARS-CoV-2 by RT-PCR. In week 35, the patient presented non-severe preeclampsia, well  
190 controlled with oral treatment with alfamethylidopa. At 36+5 weeks was decided an elective

191 delivery due to the onset of severe preeclampsia, ending in an intrapartum caesarean section.  
192 The first male twin was born: 3320 grams, APGAR test was 9 and 10 at 1 and 5 minutes,  
193 respectively, and was admitted for observation for 2 days. Second twin, male, 2360 grams,  
194 with APGAR test of 4 and 8 at 1 and 5 minutes, and he was admitted for observation for 6  
195 days. Cord blood serology was positive for IgG and negative for IgM. The placenta was clearly  
196 positive for SARS-CoV 19 by RT-PCR.

197 Case 23 (shown in Fig.4) was a woman with a bi-chorionic biamniotic twin pregnancy. The  
198 estimated risk of early-onset preeclampsia in the first trimester was 1/4440. Gestation of  
199 normal course until onset of fever, cough and malaise, with positive result in RT-PCR SARS-  
200 CoV-2 (CT: 20.2) at 38 +3 weeks of gestation. The patient presented blood pressure around  
201 150/90 mmHg, with positive creatinine protein ratio and a pneumonia on chest X-ray that  
202 required treatment with low molecular weight heparin, steroids and oxygen therapy.  
203 Laboratory tests were performed in week 38+4, HELLP syndrome was detected (59000 mm<sup>3</sup>  
204 platelets, LDH 443 U/L and GOT 43 U/L), and it was decided to elective delivery at that time by  
205 caesarean section due to HELLP and breech presentation. The birthweight of the first male  
206 twin was 2820 grams, with APGAR test 6 and 8 at 1 and 5 minutes, respectively. The  
207 birthweight of the second male twin was 2840 grams, APGAR test was 2 and 8 at 1 and 5  
208 minutes. Both were admitted to the neonatal unit and the mother had no contact with the  
209 newborns after the cesarean section. RT-PCR SARS-CoV-2 was performed on both, positive at  
210 3 and 2 days of life respectively, as well as SARS-CoV-2 serologies, which were positive at 19  
211 and 16 days of life respectively. The analysis of placenta yielded a clear positive result for  
212 SARS-CoV-2 (CT 23.1) [6].

213

## 214 **Discussion/Conclusion**

215 Previous viral epidemics have confirmed that pregnant women are at increased risk for severe  
216 virus infection [30, 31, 32]. SARS-COV-2 is not an exception, as pregnant patients with COVID-  
217 19 are at increased risk for severe illness [33, 34] and adverse pregnancy outcomes [8].  
218 Therefore, women with COVID-19 may require closer control than non-infected pregnant  
219 population.

220 Placental histopathology at term in women suffering COVID-19 has been examined in relation  
221 to disease symptoms such as systemic inflammatory responses, hypercoagulation and  
222 intervillous thrombi [35, 36]. The presence of SARS-CoV-2 in the placenta has been studied in  
223 the context of horizontal transmission of the virus [22] with an early study reporting 7.7%  
224 positivity (2/26). However, only a very limited number of studies report data that allow a direct  
225 comparison between the placental presence of SARS-CoV-2 and HDP. An early prospective  
226 cohort study [16] describes the inability to detect SARS-CoV-2 in placenta by RNA in situ  
227 hybridization in 44 women with SARS-CoV-2 diagnosis in the third trimester. Afterwards, since  
228 the first report describing the detection of SARS-CoV-2 fetal membrane samples [37], similar  
229 reports have followed. Hosier et al [38] mentions high viral load in the placenta (CT<16) of a  
230 single woman with severe preeclampsia and SARS-CoV-2 infection during the late second  
231 trimester of pregnancy. In a posterior study, a rate of 47% SARS-CoV-2 positive placenta tissue  
232 was reported in 21 women who were diagnosed (using RT-PCR) between 35 and 40 weeks of  
233 gestation [23]. In this latter study, a woman who exhibited severe placental damage delivered  
234 a baby with neurological manifestations. Based on these combined two cases, the possibility  
235 was raised that the severity of SARS-CoV-2-mediated placental pathology might be directly  
236 related to placental SARS-CoV-2 viral load.

237 Following up on these studies, we further assessed the relationship between the SARS-CoV-2  
238 viral load in placental tissue and the development of HDP in 14 HDP cases and paired controls,

239 all diagnosed with COVID-19. Out of 28 samples tested in our study, we identified 10 placental  
240 tissue samples that tested positive for SARS-CoV-2 (35.7% of total), nine of them belonging to  
241 the hypertension disorders during pregnancy (HDP) group. We observed that, among patients  
242 with SARS-CoV-2 infection during gestation, the frequency of a positive placental SARS-CoV-2  
243 PCR test was much higher in the HDP group compared to the non-HDP group. Furthermore, we  
244 detected that the percentage of cases with a positive placental SARS-CoV-2 RT-PCR test trend  
245 differently between PE and AHT ( $p= 0.065$ ). In fact, the three most severe cases of  
246 preeclampsia (cases N° 1, 11 and 23), showed higher placental viral load than all the others.  
247 Moreover, each of the three tested positive for SARS-CoV-2 in a different trimester of  
248 gestation. It has been argued that localization of SARS-CoV-2 to fetal cells such as the  
249 syncytiotrophoblast as opposed to maternal uterine cells requires detection by  
250 immunohistochemistry or RNA in situ hybridization [16]. We only applied RT-PCR and can  
251 therefore not exclude that the placenta samples we have analyzed do contain maternal tissue.  
252 Considering that maternal tissue was avoided when taking samples, and for the sake of  
253 simplicity, we interpret positive placental RT-PCR results as representative of viral load in  
254 villous placenta. This might indicate that in women susceptible to HDP, the presence of  
255 placental SARS-CoV-2 may contribute to the severity of the disorder. We suggest that a  
256 relationship between a higher viral load in placenta tissue and the severity of the hypertensive  
257 disorder deserves consideration.

258 Placental characteristics described in SARS-CoV-2 infection include maternal vascular perfusion  
259 and inflammation [35, 39]. It has been postulated that the detrimental health outcomes  
260 associated with HDP are the result of generalized endothelial and vascular dysfunction [40].  
261 Similarly, a consequence of SARS-CoV-2 infection is endothelial injury in different organs  
262 resulting directly or indirectly from the host inflammatory response [9]. Alternatively [41], it  
263 has been proposed that direct infection of syncytiotrophoblast cells in the placenta by SARS-

264 CoV-2 may cause placental dysfunction and pregnancy complications [42]. The  
265 pathophysiological mechanisms that connect placental SARS-CoV-2 with HDP remain to be  
266 established.

267 The main limitation of our study is the small sample size. Further studies with a large number  
268 of patients are required to confirm the association between high SARS-CoV-2 viral load in  
269 placenta tissue and the development of HDP. Moreover, our hospital's protocols changed as  
270 the pandemic progressed. Therefore, different methodologies have been used for viral RNA  
271 detection. As not all tests proved to be equally sensitive and specific, the use of distinct tests  
272 may have caused a discrepancy with studies published previously [13, 16, 22]. In addition, we  
273 do not have sequencing data from nasopharyngeal maternal swabs available, but all pregnant  
274 women were diagnosed before the alpha (B.1.1.7 UK) variant and delta (B.1.617.2 India) were  
275 routinely detected in our area. A final limitation to address is the fact that for each placenta  
276 we tested only a single sample. As SARS-CoV2 is not necessarily homogenously present (or  
277 absent) throughout the placenta, the identification of samples as positive or negative should  
278 be interpreted in this context.

279 Among the strengths of the study, we highlight the inclusion of women who tested positive for  
280 SARS-CoV-2 in each of the three trimesters of pregnancy. We demonstrate a higher viral load  
281 in placental tissue in the case group than in the control group and a higher frequency of  
282 infected placentas. Besides, as SARS-CoV-2 RT-PCR test carried out at the time of birth showed  
283 all mothers tested negative, we could rule out the possibility of acute maternal infection  
284 during delivery. Some cases we describe with high placenta SARS-CoV-2 levels, specifically  
285 patient 1 and patient 11, had negative RT-PCR results at the time of delivery. This data shows  
286 that placenta infection may persist in the absence of maternal infection. In the limited of cases  
287 we describe, this persistent viral presence is associated with the development of adverse  
288 perinatal outcomes.

289

290 In summary, this study assess the relationship between SARS-CoV-2 viral load in placental  
291 tissue and the maternal risk of developing gestational hypertensive disorders. We find that the  
292 presence of SARS-CoV-2 (although we do not formally prove viral infection) was more frequent  
293 placentas of the HDP group compared to placentas of COVID-19 mothers without HDP. We  
294 detect placental RNA representative of SARS-CoV-2 infection at high levels in a limited number  
295 of PE cases, and at lower levels in about 25% of placentas from COVID-19 positive mothers.  
296 There are different ways in which the infant of a PCR positive mother could be affected by  
297 SARS-CoV2: maternal inflammation and endothelial damage may be transmitted to the  
298 placenta in the form of cytokines which might modulate the fetal immune system [43].  
299 Alternatively, SARS-CoV-2 infection of the placenta may directly influence the fetal  
300 environment. The presence of placental viral RNA needs to be investigated in a much larger  
301 cohort to clarify if and in what frequency if SARS-CoV-2 infection during pregnancy does trigger  
302 gestational hypertensive disorders through placenta-related mechanisms. Our work  
303 contributes to the understanding of how SARS-CoV-2 virus affects pregnancy, which includes  
304 the possibility that placental infection contributes to pregnancy complications. Better and  
305 more detailed understanding of the placental disease process may aid or could be essential for  
306 appropriate monitoring during pregnancy and providing appropriate postnatal care.

## References [Numerical]

- 307 1. Papageorgiou AT, Deruelle P, Gunier RB, et al. Preeclampsia and COVID-19: results from the  
308 INTERCOVID prospective longitudinal study [published online ahead of print, 2021 Jun 26]. *Am J*  
309 *Obstet Gynecol.* 2021;S0002-9378(21)00561-5. doi:10.1016/j.ajog.2021.05.014
- 310 2. Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant  
311 women with and without COVID-19 Infection: The INTERCOVID Multinational Cohort  
312 Study. *JAMA Pediatr.* Published online April 22, 2021. doi:10.1001/jamapediatrics.2021.1050
- 313 3. Di Mascio D, Khalil A, Saccone G, et al. Outcome of coronavirus spectrum infections (SARS, MERS,  
314 COVID-19) during pregnancy: a systematic review and meta-analysis. *Am J Obstet Gynecol MFM.*  
315 2020;2(2):100107. doi:10.1016/j.ajogmf.2020.100107
- 316 4. Ahlberg M, Neovius M, Saltvedt S, et al. Association of SARS-CoV-2 test status and pregnancy  
317 Outcomes. *JAMA.* 2020;324(17):1782-1785. doi:10.1001/jama.2020.19124
- 318 5. Mendoza M, Garcia-Ruiz I, Maiz N, et al. Pre-eclampsia-like syndrome induced by severe COVID-  
319 19: a prospective observational study. *BJOG.* 2020;127(11):1374-1380. doi:10.1111/1471-  
320 0528.16339
- 321 6. Abadía-Cuchí N, Ruiz-Martínez S, Fabre M, et al. SARS-CoV-2 congenital infection and pre-  
322 eclampsia-like syndrome in dichorionic twins: A case report and review of the literature. *Int J*  
323 *Gynaecol Obstet.* 2021;154(2):370-372. doi:10.1002/ijgo.13749
- 324 7. Romero R, Chaiworapongsa T. Preeclampsia: a link between trophoblast dysregulation and an  
325 antiangiogenic state. *J Clin Invest.* 2013; 123:2775–2777. doi: 10.1172/JCI70431
- 326 8. Huertas A, Montani D, Savale L, et al. Endothelial cell dysfunction: a major player in SARS-CoV-2  
327 infection (COVID-19)?. *Eur Respir J.* 2020;56(1):2001634. Published 2020 Jul 30.  
328 doi:10.1183/13993003.01634-2020
- 329 9. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-  
330 19. *Lancet.* 2020;395(10234):1417-1418. doi:10.1016/S0140-6736(20)30937-5
- 331 10. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of  
332 probable bat origin. *Nature* 2020;579(7798):270–3.
- 333 11. Kumar A, Narayan RK, Kumari C, et al. SARS-CoV-2 cell entry receptor ACE2 mediated endothelial  
334 dysfunction leads to vascular thrombosis in COVID-19 patients. *Med Hypotheses.*  
335 2020;145:110320. doi:10.1016/j.mehy.2020.110320
- 336 12. Castro, P., Palomo, M., Moreno-Castaño, A.B. et al. Is the endothelium the missing link in the  
337 pathophysiology and treatment of COVID-19 complications?. *Cardiovasc Drugs Ther* (2021).  
338 <https://doi.org/10.1007/s10557-021-07207-w>
- 339 13. Schwartz DA, Morotti D, Beigi B, Moshfegh F, Zafaranloo N, Patanè L. Confirming vertical fetal  
340 infection with coronavirus disease 2019: neonatal and pathology criteria for early onset and  
341 transplacental transmission of severe acute respiratory syndrome coronavirus 2 from infected  
342 pregnant mothers. *Arch Pathol Lab Med.* 2020 Dec 1;144(12):1451-1456. doi:  
343 10.5858/arpa.2020-0442-SA.
- 344 14. Patanè L, Morotti D, Giunta MR, Sigismondi C, Piccoli MG, Frigerio L, et al. Vertical transmission  
345 of coronavirus disease 2019: severe acute respiratory syndrome coronavirus 2 RNA on the fetal  
346 side of the placenta in pregnancies with coronavirus disease 2019–positive mothers and  
347 neonates at birth. *Am J Obstet Gynecol MFM.* 2020 Aug;2(3):100145.
- 348 15. Kirtsman M, Diambomba Y, Poutanen SM, Malinowski AK, Vlachodimitropoulou E, Parks WT, et  
349 al. Probable congenital sars-cov-2 infection in a neonate born to a woman with active sars-cov-2  
350 infection. *Cmaj.* 2020;192(24):E647–50.
- 351 16. Edlow AG, Li JZ, Collier AY, et al. Assessment of maternal and neonatal SARS-CoV-2 viral load,  
352 transplacental antibody transfer, and placental pathology in pregnancies during the COVID-19  
353 Pandemic. *JAMA Netw Open.* 2020;3(12):e2030455. Published 2020 Dec 1.  
354 doi:10.1001/jamanetworkopen.2020.30455

- 355 17. Smithgall MC, Liu-Jarin X, Hamele-Bena D, Cimic A, Mourad M, Debelenko L, Chen X. Third-  
356 trimester placentas of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive  
357 women: histomorphology, including viral immunohistochemistry and in-situ hybridization.  
358 *Histopathology*. 2020 Dec;77(6):994-999. doi: 10.1111/his.14215. Epub 2020 Sep 26. PMID:  
359 32692408; PMCID: PMC7405484.
- 360 18. Mulvey JJ, Magro CM, Ma LX, Nuovo GJ, Baergen RN. Analysis of complement deposition and  
361 viral RNA in placentas of COVID-19 patients. *Ann Diagn Pathol*. 2020;46:151530.  
362 doi:10.1016/j.anndiagpath.2020.151530
- 363 19. Raschetti R, Vivanti AJ, Vauloup-Fellous C, et al. Synthesis and systematic review of reported  
364 neonatal SARS-CoV-2 infections. *Nat Commun*. 2020;11(1): 5164. doi:10.1038/s41467-020-  
365 18982-9
- 366 20. Yan J, Guo J, Fan C, et al. Coronavirus disease 2019 in pregnant women: a report based on 116  
367 cases. *Am J Obstet Gynecol*. 2020;223(1):111.e1-111.e14. doi:10.1016/j.ajog.2020.04.014
- 368 21. Bwire GM, Njiro BJ, Mwakawanga DL, Sabas D, Sunguya BF. Possible vertical transmission and  
369 antibodies against SARS-CoV-2 among infants born to mothers with COVID-19: A living systematic  
370 review. *J Med Virol*. 2021 Mar;93(3):1361-1369. doi: 10.1002/jmv.26622. Epub 2020 Nov 10.  
371 PMID: 33090535.
- 372 22. Kotlyar AM, Grechukhina O, Chen A, et al. Vertical transmission of coronavirus disease 2019: a  
373 systematic review and meta-analysis. *Am J Obstet Gynecol*. 2021;224(1):35-53.e3.  
374 doi:10.1016/j.ajog.2020.07.049
- 375 23. Cribiù FM, Erra R, Pagni L, et al. Severe SARS-CoV-2 placenta infection can impact neonatal  
376 outcome in the absence of vertical transmission. *J Clin Invest*. 2021;131(6):e145427.  
377 doi:10.1172/JCI145427
- 378 24. Lou-Mercadé AC, Gavín O, Oros D, et al. Prevention of thrombosis in pregnant women with  
379 suspected SARS-CoV-2 infection: clinical management algorithm. *Ultrasound Obstet Gynecol*.  
380 2020;56(1):111-112. doi:10.1002/uog.22096
- 381 25. Gao Z, Xu Y, Sun C, et al. A systematic review of asymptomatic infections with COVID-19. *J*  
382 *Microbiol Immunol Infect*. 2021;54(1):12-16. doi:10.1016/j.jmii.2020.05.001
- 383 26. Oros D, Strunk M, Breton P, et al. Altered gene expression in human placenta after suspected  
384 preterm labour. *Placenta*. 2017;55:21-28. doi:10.1016/j.placenta.2017.04.025.
- 385 27. Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy: ISSHP classification,  
386 diagnosis, and management recommendations for international practice. *Hypertension*.  
387 2018;72(1):24-43. doi:10.1161/HYPERTENSIONAHA.117.10803
- 388 28. Serra B, Mendoza M, Scazzocchio E, Meler E, Nolla M, Sabrià E, Rodríguez I, Carreras E. A new  
389 model for screening for early-onset preeclampsia. *Am J Obstet Gynecol*. 2020 Jun;222(6):608.e1-  
390 608.e18. doi: 10.1016/j.ajog.2020.01.020. Epub 2020 Jan 21. PMID: 31972161.
- 391 29. Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. *Am J*  
392 *Reprod Immunol*. 2015;73(3):199-213. doi:10.1111/aji.12355
- 393 30. Meijer WJ, van Noortwijk AG, Bruinse HW, Wensing AM. Influenza virus infection in pregnancy: a  
394 review. *Acta Obstet Gynecol Scand*. 2015 Aug;94(8):797-819. doi: 10.1111/aogs.12680. Epub  
395 2015 Jun 13. PMID: 26012384.
- 396 31. Olgun NS. Viral infections in pregnancy: A Focus on Ebola Virus. *Curr Pharm Des*. 2018;24(9):993-  
397 998. doi: 10.2174/1381612824666180130121946. PMID: 29384053; PMCID: PMC6419752.
- 398 32. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and  
399 perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-  
400 analysis. *BMJ* 2020;370:m3320-m3320.
- 401 33. Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of  
402 reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy Status - United  
403 States, January 22-October 3, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(44):1641-1647.  
404 Published 2020 Nov 6. doi:10.15585/mmwr.mm6944e3

- 405 34. Patberg ET, Adams T, Rekawek P, et al. Coronavirus disease 2019 infection and placental  
406 histopathology in women delivering at term [published correction appears in Am J Obstet  
407 Gynecol. 2021 Jun 10;:]. Am J Obstet Gynecol. 2021;224(4):382.e1-382.e18.  
408 doi:10.1016/j.ajog.2020.10.020
- 409 35. Shanes ED, Mithal LB, Otero S, Azad HA, Miller ES, Goldstein JA. Placental pathology in COVID-19.  
410 Preprint. *medRxiv*. 2020;2020.05.08.20093229. Published 2020 May 12.  
411 doi:10.1101/2020.05.08.20093229
- 412 36. Prabhu M, Cagino K, Matthews KC, et al. Pregnancy and postpartum outcomes in a universally  
413 tested population for SARS-CoV-2 in New York City: a prospective cohort study. BJOG.  
414 2020;127(12):1548-1556. doi:10.1111/1471-0528.16403
- 415 37. Penfield CA, Brubaker SG, Limaye MA, et al. Detection of severe acute respiratory syndrome  
416 coronavirus 2 in placental and fetal membrane samples. Am J Obstet Gynecol MFM.  
417 2020;2(3):100133. doi:10.1016/j.ajogmf.2020.100133
- 418 38. Hosier H, Farhadian SF, Morotti RA, et al. SARS-CoV-2 infection of the placenta. J Clin Invest.  
419 2020;130(9):4947-4953. doi:10.1172/JCI139569
- 420 39. Lu-Culligan A, Chavan AR, Vijayakumar P, et al. SARS-CoV-2 infection in pregnancy is associated  
421 with robust inflammatory response at the maternal-fetal interface. Preprint. *medRxiv*.  
422 2021;2021.01.25.21250452. Published 2021 Jan 26. doi:10.1101/2021.01.25.21250452
- 423 40. Brennan LJ, Morton JS, Davidge ST. Vascular dysfunction in preeclampsia. Microcirculation. 2014  
424 Jan;21(1):4-14. doi: 10.1111/micc.12079. PMID: 23890192.
- 425 41. Levy A, Yagil Y, Bursztyn M, Barkalifa R, Scharf S, Yagil C. ACE2 expression and activity are  
426 enhanced during pregnancy. Am J Physiol Regul Integr Comp Physiol. 2008 Dec;295(6):R1953-61.  
427 doi: 10.1152/ajpregu.90592.2008. Epub 2008 Oct 22.
- 428 42. Li M, Chen L, Zhang J, Xiong C, Li X. The SARS-CoV-2 receptor ACE2 expression of maternal-fetal  
429 interface and fetal organs by single-cell transcriptome study. PLoS One. 2020;15(4):e0230295.  
430 Published 2020 Apr 16. doi:10.1371/journal.pone.0230295
- 431 43. Matute J, Finander B, Pepin D, et al. Single-cell immunophenotyping of the fetal immune  
432 response to maternal SARS-CoV-2 infection in late gestation. Preprint. Res Sq. 2021;rs.3.rs-  
433 311000. Published 2021 Mar 16. doi:10.21203/rs.3.rs-311000/v1



It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

## Figure Legends

**Figure 1.** % RT-PCR positive placenta: cases group vs control group. Ten placentas (35.7% = 3.57% + 32.14%) tested positive for SARS-CoV-2 RNA. Nine positive placentas in the cases group (9/28, 32.14%) while in control group only one placenta were positive (1/28, 3.57%). Seven (7/28, 25%) belong to women diagnosed with preeclampsia vs two of nine belong to women diagnosed with gestational hypertension (2/28, 7.14%).

**Figure 2.** Timeline of case 1. TPAL: term, pre-term, abortion, life; LMWH: low molecular weight heparin; PAPP-A: pregnancy-associated plasma protein-A; MoM: multiple of median; BP: Mean Arterial Blood Pressure; Uta PI: uterine artery resistance pulsatility index; w: weeks; EFW: estimated fetal weight; PI UA: umbilical artery pulsatility index; PI MCA: fetal middle cerebral artery pulsatility index; IUGR: Intrauterine growth restriction; BP: blood pressure.

**Figure 3.** Timeline of case 11. TPAL: term, pre-term, abortion, life; LMWH: low molecular weight heparin; PAPP-A: pregnancy-associated plasma protein-A; MoM: multiple of median; BP: Mean Arterial Blood Pressure; Uta PI: uterine artery resistance pulsatility index; w: weeks; EFW: estimated fetal weight; PI UA: umbilical artery pulsatility index; PI MCA: fetal middle cerebral artery pulsatility index; IUGR: Intrauterine growth restriction; BP: blood pressure; NA: neonatal admission.

**Figure 4.** Timeline of case 23. TPAL: term, pre-term, abortion, life; LMWH: low molecular weight heparin; PAPP-A: pregnancy-associated plasma protein-A; MoM: multiple of median; BP: Mean Arterial Blood Pressure; Uta PI: uterine artery resistance pulsatility index; w: weeks; EFW: estimated fetal weight; PI UA: umbilical artery pulsatility index; PI MCA: fetal middle cerebral artery pulsatility index; IUGR: Intrauterine growth restriction; BP: blood pressure; NA: neonatal admission.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .


	CASE GROUP (n=14)	CONTROL GROUP (n=14)	p
<b>Demographic maternal data</b>			
Maternal age (SD), years	31.93 (6.6)	30.36 (5.8)	0.506
Maternal weight (SD), kg	69.32 (10.5)	68.57 (13.2)	0.868
Caucasian (%)	9 (64.3)	4 (28.6)	0.063
1 <sup>o</sup> trimester high risk for Preeclampsia (%)	5 (35.7)	3 (21.4)	0.194
Diabetes mellitus (%)	0 (0)	1 (7.14)	0.317
Nullipara (%)	4 (28.6)	7 (50)	0.317
<b>Maternal and neonatal outcome at delivery</b>			
Gestational age at birth mean (SD), days	268.1 (10.8)	278.9 (7.8)	0.005
Birth weight, mean (SD), kg	2852.5 (467.0)	3282.9 (435.9)	0.018
SGA (<10th centile) (%)	4 (28.6)	1 (7.2)	0.146
Induced labor (%)	12 (85.1)	4 (28.6)	0.003
Cesarean delivery (%)	5 (35.7)	0 (0)	0.015
pH<7.1 (%)	2 (14.3)	0(0)	0.541
Preterm birth (<37 wk gestation) (%)	3 (21.4)	0(0)	0.072
<b>Description of SARS-CoV-2</b>			
Trimester of SARS-CoV-2 infection			
1 <sup>o</sup> (%)	1 (7.2)	1 (7.2)	1
2 <sup>o</sup> (%)	5 (35.7)	5 (35.7)	
3 <sup>o</sup> (%)	8 (57.1)	8 (57.1)	
COVID-19 Symptoms			
No	6 (42.9)	7(50)	0.341
Mild	6 (42.9)	7 (50)	
Severe	2 (14.2)	0 (0)	
Interval from diagnosis of SARS-CoV-2 to delivery (SD), d	61.86 (54.79)	72.64 (57.7)	0.616
Positive SARS-CoV-2 RT-PCR Placenta tissue (CT<37) (%)	9 (64.3)	1 (7.2)	0.009
Neonatal IgG (%)*	6 (42.9)	7 (50)	0.688
Table 1. SD: standard deviation; CT: cycle threshold value RT-PCR; SGA: small for gestational age *Analyzed 24 of 28.			

Table 1. Demographic data and obstetrical and SARS-CoV-2 infection characteristics





		DIAGNOSIS SARS-COV-2		DIAGNOSIS HDP			DELIVERY						NEONATAL ANTIBODIES SARS-CoV-2	
	Nº	SYN	GA	HDP	GA	Interval DEL-HDP (Days)	GA	Interval DEL - SARS (Days)	RT-PCR Result nasopharyngeal*	RT-PCR Result placenta tissue	CT RT-PCR Placenta tissue	Copy number/µl	IgG	IgM+IgA
CASE	1	No	8+0	S-PE	35+0	185	35+2	187	Negative	Positive	28.7	1158.3	Negative	N/A
CONTROL	2	Mild	9+3				38+5	202	Negative	Negative	≥40	0	Negative	N/A
CASE	3	No	21+3	S-PE	36+3	105	36+5	107	N/A	Positive	33.5	41.9	Negative	Negative
CONTROL	4	Mild	20+4				39+5	133	N/A	Negative	≥40	0	Positive	Negative
CASE	5	Mild	24+4	GHT	37+1	88	39+5	106	Negative	Positive	32.4	91.8	Positive	Negative
CONTROL	6	Mild	23+4				40+2	117	Positive	Negative	≥40	0	Positive	Negative
CASE	7	Mild	24+6	PE	36+4	82	37+1	86	Negative	Positive	31.7	150.5	Positive	Negative
CONTROL	8	Mild	25+1				39+2	99	Negative	Positive	33.9	32.1	Positive	Negative
CASE	9	Mild	25+6	GHT	38+0	85	40+1	99	Negative	Positive	33.1	57.4	Positive	Negative
CONTROL	10	Mild	25+5				41+2	109	Negative	Negative	≥40	0	Positive	Negative
CASE	11	Mild	26+6	S-PE	35+0	57	36+5	71	Negative	Positive	23.1	56377.8	Positive	Negative
CONTROL	12	Mild	27+4				40+2	89	Negative	Negative	≥40	0	Positive	Negative
CASE	13	Mild	29+4	GHT	35+3	42	39+6	73	Negative	Negative	≥40	0	N/A	N/A
CONTROL	14	No	30+0				39+1	64	Negative	Negative	≥40	0	N/A	N/A
CASE	15	Severe	30+0	PE	33+3	25	37+2	52	N/A	Negative	≥40	0	Positive	Negative
CONTROL	16	No	29+4				41+0	80	N/A	Negative	≥40	0	Positive	Negative
CASE	17	No	31+0	GHT	36+5	63	40+4	67	Negative	Negative	≥40	0	N	N/A
CONTROL	18	No	31+2				39+6	60	Negative	Negative	39.5	0	N	N/A
CASE	19	No	36+2	PE	37+5	11	38+0	13	Positive	Positive	35.2	13.4	N	N/A
CONTROL	20	No	36+4				40+2	26	Positive	Negative	≥40	0	N	N/A
CASE	21	No	37+6	PE	37+6	0	38+1	2	Negative	Positive	33.9	31.8	N	N/A
CONTROL	22	No	37+5				37+5	0	Positive	Negative	≥40	0	Positive	Negative
CASE	23	Severe	38+3	S-PE	38+3	0	38+4	1	Positive	Positive	15.1	14127744	Positive	Negative
CONTROL	24	Mild	38+3				38+3	0	Positive	Negative	≥40	0	N	N/A

CASE	25	No	38+5	PE	38+5	0	38+6	1	Positive	Negative	≥40	0	Negative	N/A
CONTROL	26	No	38+0				40+4	18	Positive	Negative	≥40	0	Negative	N/A
CASE	27	No	39+0	GHT	39+0	0	39+2	2	Positive	Negative	≥40	0	N/A	N/A
CONTROL	28	No	38+5				41+2	19	Negative	Negative	≥40	0	N/A	N/A
Table 2. Syn: Symptoms of SARS-COV-2 infection; GA: gestational age (week + days); HDP: hypertensive disorders of pregnancy; GHT: Gestational hypertension; PE: preeclampsia; S-PE: severe preeclampsia; DELIV-PE (Days): interval from diagnosis of COVID19 to HDP diagnosis, days; DELIV-SARS (Days): interval from diagnosis of COVID19 to delivery, days; CT: cycle threshold value RT-PCR; R: result; P: positive; N: negative; N/A: not available;														
* RT-PCR was only performed if the latest negative RT-PCR test was more than 3 months ago.														
	the squares marked in blue color correspond to controls without HDP													



Case 1



Placenta



Case 11

